The global pharmaceutical drug delivery market, valued at US$1,831.1 billion in 2023, is forecasted to grow at a robust CAGR of 5.5%, reaching US$1,949.4 billion in 2024 and an impressive US$2,546.0 billion by 2029. The rising global incidence of chronic diseases, the launch of new products, increased investment in pharmaceutical R&D, emphasis on patient comfort and compliance, and government initiatives to provide affordable drug delivery products are some of the factors driving market growth. Other contributing factors include the growing geriatric population and the rising prevalence of diabetes, hypertension, cancer, and infectious diseases. The market has also shown trends such as the modernization of drug delivery technologies, patient preference for home-based care, supportive reimbursement policies, and government-backed healthcare development, all of which are expected to support the growth of hospitals and ambulatory diagnostic centers, improving access to pharmacological therapies for patients.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085
Browse in-depth TOC on "Pharmaceutical Drug Delivery Market"
907 - Tables
63 - Figures
718 - Pages
Injectable Drug Delivery Sector Leading the Market
Injectable drug delivery holds the largest market share among administration routes, primarily due to its effectiveness in managing chronic diseases. Injectables offer advantages over oral medications by improving patient adherence and reducing dosing frequency. Advances in injectable technologies, aimed at minimizing needle pain and complications, are further fueling growth in this segment.
Hospitals to Experience Rapid Market Expansion
The pharmaceutical drug delivery market is segmented by facility of use, including hospitals, ambulatory surgical centers, diagnostic centers, home care settings, and other facilities. Hospitals are projected to see the most substantial growth due to high patient traffic, increased need for various medications and delivery devices, a rise in surgeries, and a growing prevalence of chronic diseases, which are driving up hospital admissions and, consequently, the demand for drug delivery solutions.
Asia Pacific Region Poised for Significant Growth
The pharmaceutical drug delivery market is divided into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia Pacific is expected to register the highest growth rate in the coming years, driven by the presence of leading pharmaceutical companies, a growing patient population with chronic conditions, increased healthcare spending, and government efforts to enhance access to pharmaceutical treatments in the region.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085
Major Market Players and Their Strategies
Prominent players in the pharmaceutical drug delivery market include Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Sanofi (France), Bayer AG (Germany), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim International GmbH (Germany), and AstraZeneca (UK).
Johnson & Johnson Services, Inc. Focuses on Innovation
Johnson & Johnson Services, Inc., a leading player in the pharmaceutical drug delivery market, offers a broad range of products across major therapeutic areas. The company emphasizes product innovation and R&D, with an annual R&D expenditure of approximately USD 15 million, accounting for 17.7% of its total revenue. Johnson & Johnson has a strong presence in North America, Europe, Asia Pacific, and Africa. To ensure continued growth, the company pursues partnerships, agreements, and mergers and acquisitions to expand its product portfolio and regional reach.
Novartis AG: A Key Market Leader
Novartis AG stands out in the pharmaceutical drug delivery market due to its extensive global presence and strong brand recognition. The company offers a comprehensive portfolio in therapeutic areas such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology. Novartis focuses on high-growth fields and prioritizes resource allocation to these areas. The company strengthens its business through strategic partnerships, collaborations, and agreements to enhance its operations and market position.
For more information, Inquire Now!
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian